Automatic volumetric capillary cytometry for counting white cells in white cell-reduced plateletpheresis components

被引:29
作者
Adams, MR
Johnson, DK
Busch, MP
Schembri, CT
Hartz, TP
Heaton, WA
机构
[1] IRWIN MEM BLOOD CTR,SCI SERV,SAN FRANCISCO,CA
[2] IRWIN MEM BLOOD CTR,RES & SCI SERV,SAN FRANCISCO,CA
[3] UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143
[4] BIOMETR IMAGING INC,DEV,MT VIEW,CA
关键词
D O I
10.1046/j.1537-2995.1997.37197176948.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: As the benefits of white cell (WBC)-reduced blood components become increasingly apparent, the need has arisen for a simple, automated WBC-counting technique that is sensitive to tow WBC concentrations. Automated Volumetric capillary cytometry was evaluated for its ability to quantify residual WBCs in WBC-reduced platetetpheresis components. STUDY DESIGN AND METHODS: The volumetric capillary cytometry system evaluated uses a laser to excite fluorescent dye-labeled nucleated cells. The number of nucleated cells per mu L is reported. Four studies were performed: linearity, precision of results near the value of 5 x 10(6) WBCs per unit, the limit of detection, and correlation to the Nageotte manual counting method. RESULTS: Assay Values correlated to expected values (range, 0-125 WBC/mu L) with an r(2) >0.99. In the range of 5 x 10(6) WBCs per unit, the CV was 8.5 percent, and concentration differences of 0.15 log(10) were detectable. The limit of detection was 1.0 WBCs per mu L (95% upper confidence limit). The assay correlated to the Nageotte method with an r(2) of 0.98, slope of 1.0, and y-intercept of 2.0 WBCs per mu L. Assay results were 10 to 15 percent higher than Nageotte results, in samples with values near 5 x 10(6) WBCs per unit. Technician time per sample was 2 to 3 minutes. CONCLUSION: Volumetric capillary cytometry is precise and sensitive to small differences in WBC concentration in the range of clinical interest. The device provides an efficient new method for quality assurance and control of WBC-reduced plateletpheresis products.
引用
收藏
页码:29 / 37
页数:9
相关论文
共 32 条
[1]  
*BAXT HEALTHC, 1995, FCRP0592 BAXT HEALTH
[2]  
BLAJCHMAN MA, 1991, SEMIN HEMATOL, V28, P14
[3]  
BLUMBERG N, 1994, ARCH PATHOL LAB MED, V118, P371
[4]   LEUKODEPLETED-ABO-IDENTICAL BLOOD COMPONENTS IN THE TREATMENT OF HEMATOLOGIC MALIGNANCIES - A COST-ANALYSIS [J].
BLUMBERG, N ;
HEAL, JM ;
KIRKLEY, SA ;
DIPERSIO, JF ;
RAPOPORT, AP ;
ROWE, JM .
AMERICAN JOURNAL OF HEMATOLOGY, 1995, 48 (02) :108-115
[5]   A COMPARISON OF FILTERED LEUKOCYTE-REDUCED AND CYTOMEGALOVIRUS (CMV) SERONEGATIVE BLOOD PRODUCTS FOR THE PREVENTION OF TRANSFUSION-ASSOCIATED CMV INFECTION AFTER MARROW TRANSPLANT [J].
BOWDEN, RA ;
SLICHTER, SJ ;
SAYERS, M ;
WEISDORF, D ;
CAYS, M ;
SCHOCH, G ;
BANAJI, M ;
HAAKE, R ;
WELK, K ;
FISHER, L ;
MCCULLOUGH, J ;
MILLER, W .
BLOOD, 1995, 86 (09) :3598-3603
[6]  
BUSCH MP, 1992, BLOOD, V80, P2128
[7]  
DEITZ L, 1996, CYTOMETRY, V23, P177
[8]  
DIEM K, 1962, DOCUMENTA GEIGY SCI, P46
[9]   Practical guidelines for process validation and process control of white cell-reduced blood components: Report of the biomedical excellence for safer transfusion (BEST) working party of the international society of blood transfusion (ISBT) [J].
Dumont, LJ ;
Dzik, WH ;
Rebulla, P ;
Brandwein, H .
TRANSFUSION, 1996, 36 (01) :11-20
[10]  
DUMONT LJ, 1993, TRANSFUSION, V33, pS91